Cimzia: new TNF-alpha inhibitor

Cimzia is a new addition to the management of moderate to severely active rheumatoid arthritis in combination with methotrexate or as monotherapy.

PHARMACOLOGY

Certolizumab pegol is a PEGylated formulation of a humanized monoclonal antibody specific for tnf-α.

CLINICAL STUDIES

In two studies comparing the use of certolizumab and MTX to placebo and MTX, significantly more patients in the certolizumab groups achieved the American College of Rheumatology 20 per cent criteria for improvement (ACR20) at 24 weeks.1,2

The most common adverse effects in the trials were headache, hypertension, UTI, URTI and back pain.1,2

View Cimzia drug record

REFERENCES

  1. Keystone E et al. Arthritis Rheumatism 2008; 58:3319-29.
  2. Smolen J et al. Ann Rheum Dis 2009; 68:797-804.

Further information: UCB

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Loss of taste and smell and neurological aspects of...

First triple combination MDI licensed for asthma

First triple combination MDI licensed for asthma

Trimbow (beclometasone/formoterol/glycopyrronium) can...